αβ TCR Design and Construction Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs is dedicated to providing comprehensive CRO services to accelerate your different next-generation T cell immunotherapies. Given the numerous advantages of γδ T cells over αβ T cells, many approaches to using γδ T cells for antitumor therapy have been discovered. αβ TCR-engineered γδ T cell therapy is a new alternative strategy for adoptive T-cell transfer. Our scientists and technicians can provide services for αβ TCR design and construction in αβ TCR-engineered γδ T cell therapy.

αβ TCR and Co-receptor

αβ TCR s recognize peptides presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs). The binding of the TCR to the MHC molecule containing the antigen peptide is a little unstable and so co-receptors are required. αβ T cells express the co-receptors CD4 and CD8 that are required for T cell activation. Unlike MHC-restricted αβ T cells, the majority of γδ T cells are activated in an MHC-independent manner. In addition to expressing a distinct form of the antigen receptor, these γδ T cells generally do not express CD4 or CD8. Therefore, introducing αβ TCR into γδ T cells alone does not provide sufficient affinity to recognize MHC-peptide complexes due to the lack of CD8 co-receptor. TCR gene transfer into γδ T cells requires the cotransfer of co-receptor and the joint introduction of TCR and coreceptor genes can be achieved readily. γδ T cells co-transduced with TCR αβ and CD8 αβ genes can acquire cytotoxicity against tumor cells and produce cytokines in both αβ- and γδ-TCR-dependent manners.

αβ TCR and Co-receptor Fig.1 αβTCR engineered γδ T cell.

The major challenge in the development of αβ TCR-based cell therapy is the identification of suitable target antigens that are presented as peptides in the context of specific HLA alleles and a suitable TCR that recognizes the cognate pMHC with optimal affinity. We provide neoantigen discovery and TCR generation services that include next-generation sequencing and single-cell RNA sequencing for TCR identification, novel epitope prediction methods, mass-spectrometry, and T cell-based validation assays, to generate TCRs with optimal affinity and high specificity.

With years of experience in CRO services for immunotherapy projects, Creative Biolabs is confident in providing one-stop αβ TCR-engineered γδ T development services to meet your research purposes. We provide services for the design and construction of the αβ TCR vector and its coreceptor CD8 vector. If you are interested in our services, please contact our scientists who will work with you to provide a solution that works for your project.

Reference

Hiasa, A.; et al. Rapid αβ TCR-mediated responses in γδ T cells transduced with cancer-specific TCR genes. Gene therapy, 2009, 16(5): 620-628.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION